<DOC>
	<DOCNO>NCT01425476</DOCNO>
	<brief_summary>This biomarker study goal measure change protein gene methylation . This study intend use diagnosing , mitigate , treat , cure , prevent disease . The purpose study determine Vitamin D ( cholecalciferol ) alone combination celecoxib ( Celebrex , non-steroidal anti-inflammatory drug , NSAID ) , decrease breast cancer risk effect certain biological indicator ( biomarkers ) breast cancer risk ( call PGE2 , COX-2 , 15-PGDH ) cell change breast .</brief_summary>
	<brief_title>Changes Breast Cancer Biomarkers Using Synergistic Prostaglandin Inhibitors</brief_title>
	<detailed_description>This biomarker study goal measure change protein RNA expression . This study intend use diagnosing , mitigate , treat , cure , prevent disease . 66 woman high risk breast cancer ( gail risk &gt; /= 1.66 % 5 year risk , personal family history ) recruit enrol . 22 woman randomize arm , anticipation 2 woman group evaluable , leave 20 group evaluation . A combination vitamin D celecoxib act synergistically decrease breast cancer risk decrease cell proliferation mammary epithelium action prostaglandin synthesis metabolism . Specific Aims : In woman increase breast cancer risk , determine effect vitamin D , without celecoxib , 1 . PG synthesis metabolism , measurement 15-PGDH , COX-2 , PGE2 breast Rationale : 1,25 ( OH ) 2D , active form vitamin D , show vitro decrease PGE2 interfere production increase breakdown , lead low cell proliferation . Celecoxib potentiate antiproliferative effect , allow much low dose agent use combination isolation . 2 . Proliferative activity breast , measure Mammary Ductoscopy ( MD ) cell morphology Rationale : Both MD Nipple Aspirate Fluid ( NAF ) contain ductal epithelial cell , MD sample contain cell cytologic review NAF . Findings MD cytology correlate likelihood breast cancer ( 2 ) , NAF cytology relate breast cancer risk improve risk stratification ( 3 ) , bioactive food component alter NAF cytology ( 4 ) . 3 . Circulating level 25 ( OH ) D , 1,25 ( OH ) 2D , celecoxib , determine level compound correlate response marker PG synthesis metabolism cell proliferation .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Prostaglandin Antagonists</mesh_term>
	<criteria>Women 18 year age old Increased risk breast cancer ( demonstrate strong family history [ one 1st degree two 2nd degree relative ] , history DCIS , IBC , precancerous change breast ) . OR Gail Model risk develop IBC 5year period &gt; 1.66 % Women history breast cancer , must free disease finish treatment ECOG Performance Status score 01 Premenopausal woman must pregnant . History bilateral mastectomy , bilateral breast irradiation Significant medical psychiatric problem make participant poor candidate Evidence excess use narcotic drug dependency Have pregnant lactating past 2 year Significant history peptic ulcer disease upper gastrointestinal bleeding History severe congestive heart failure require hospitalization intervention History asthma require medication treatment Allergy sulfonamide NSAID medication History myocardial infarction stroke Currently Coumadin Currently Tamoxifen ( nolvadex ) , Evista ( raloxifene ) , Femara ( letrozole ) , Arimidex ( anastrozole ) , Aromasin ( exemestane ) Undergone prior subaeolar breast surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>breast</keyword>
	<keyword>high risk woman</keyword>
	<keyword>biomarkers</keyword>
	<keyword>vitamin D</keyword>
</DOC>